^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCL20 overexpression

    i
    Other names: CCL20, C-C Motif Chemokine Ligand 20, LARC, Small Inducible Cytokine Subfamily A (Cys-Cys), Member 20, Liver And Activation-Regulated Chemokine, Macrophage Inflammatory Protein 3 Alpha, Chemokine (C-C Motif) Ligand 20, Small-Inducible Cytokine A20, C-C Motif Chemokine 20, CC Chemokine LARC, MIP-3-Alpha, MIP-3a, SCYA20, MIP3A, CKb4, ST38, Beta Chemokine Exodus-1, Beta-Chemokine Exodus-1, Exodus-1, Exodus
    Entrez ID:
    6364
    Related biomarkers:
    Expression
    Others
    12ms
    Clinicopathological characteristics and molecular analysis of lymphocyte-rich hepatocellular carcinoma. (PubMed, Hum Pathol)
    In conclusion, there were no significant differences in clinicopathological characteristics between LR-HCC and non-LR-HCC, except for gross and LR microscopic features. CCL20 expression in LR-HCC may contribute to infiltration of large numbers of CD8-positive lymphocytes.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CCL20 (C-C Motif Chemokine Ligand 20) • CCR6 (C-C Motif Chemokine Receptor 6)
    |
    CD20 positive • CD8 positive • CCL20 overexpression
    1year
    CCL20 is a potential therapeutic target associated with immune infiltration in breast cancer. (PubMed, J Int Med Res)
    CCL20 is a prognosis-related biomarker in breast cancer on the basis of its correlation with immune infiltration levels and has potential to also be a therapeutic target.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CCL20 (C-C Motif Chemokine Ligand 20)
    |
    CCL20 overexpression